Higher Vedolizumab Clearance Associates with Poor Therapeutic Outcomes during Intravenous Vedolizumab Maintenance Therapy in Crohn’s Disease

Lay Summary Vedolizumab clearance (CL) outperforms serum trough concentrations in predicting therapeutic outcomes in Crohn’s disease. Higher CL was significantly associated with reduced remission rates, supporting CL as a pharmacokinetic marker for optimizing vedolizumab therapy.